Table 56:
Scenario Analysis Results, nVNS for Acute Treatment, Cluster Headache
| Analysis | Budget impact, $ milliona | |||||
|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Totalb | |
| Reference case | 0.76 | 1.54 | 2.36 | 3.19 | 4.04 | 11.88 |
| 1: nVNS provided free for the first 93 days | 0.49 | 1.01 | 1.54 | 2.08 | 2.64 | 7.77 |
| 2: Annual uptake of 2% per year, up to 10% in year 5 | 1.51 | 3.09 | 4.72 | 6.37 | 8.08 | 23.77 |
| 3: Annual uptake of 20% per year, up to 100% in year 5 | 15.1 | 30.88 | 47.15 | 63.74 | 80.81 | 237.69 |
| 4a: Cost of the nVNS device decreased by 25% | 0.57 | 1.15 | 1.76 | 2.39 | 3.03 | 8.91 |
| 4b: Cost of the nVNS device increased by 25% | 0.94 | 1.93 | 2.94 | 3.98 | 5.05 | 14.86 |
Abbreviation: nVNS, noninvasive vagus nerve stimulation.
a
In 2024 Canadian dollars.
b
Results may appear inexact due to rounding.